The current study showed that before treatment, the effective group had lower levels of hypertension, CHD, valvular heart disease, galectin-3, RDW, Hepc, and HS and higher levels of ferritin than the non-effective group (P < 0.05). This evidence concerns the gene LGALS3 and hypertensive disorder.